217 related articles for article (PubMed ID: 24013983)
1. Hypercalcemia secondary to gastrointestinal stromal tumors: parathyroid hormone-related protein independent mechanism?
Jasti P; Lakhani VT; Woodworth A; Dahir KM
Endocr Pract; 2013; 19(6):e158-62. PubMed ID: 24013983
[TBL] [Abstract][Full Text] [Related]
2. Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
Miyoshi N; Tanaka H; Ito T; Katayama Y; Niimi H; Hyodo H; Kimura A
Int J Hematol; 2005 Nov; 82(4):333-7. PubMed ID: 16298826
[TBL] [Abstract][Full Text] [Related]
3. Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature.
Hygum K; Wulff CN; Harsløf T; Boysen AK; Rossen PB; Langdahl BL; Safwat AA
BMC Cancer; 2015 Oct; 15():788. PubMed ID: 26499069
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcaemia in a patient with a gastrointestinal stromal tumour.
Beckers MM; Slee PH
Clin Endocrinol (Oxf); 2007 Jan; 66(1):148. PubMed ID: 17201815
[No Abstract] [Full Text] [Related]
5. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia in the setting of advanced gastrointestinal stromal tumor.
Guiteau J; Fanucchi M; Folpe A; Staley CA; Kooby DA
Am Surg; 2006 Dec; 72(12):1225-30. PubMed ID: 17216825
[TBL] [Abstract][Full Text] [Related]
7. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
8. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Nishida T; Yoshidome K; Tori M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
[No Abstract] [Full Text] [Related]
10. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
[TBL] [Abstract][Full Text] [Related]
11. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
12. Humoral Hypercalcemia in Uterine Cancers: A Case Report and Literature Review.
Motilal Nehru V; Garcia G; Ding J; Kong F; Dai Q
Am J Case Rep; 2017 Jan; 18():22-25. PubMed ID: 28057913
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
Bauer S; Hagen V; Pielken HJ; Bojko P; Seeber S; Schütte J
Anticancer Drugs; 2002 Sep; 13(8):847-9. PubMed ID: 12394270
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Hassan BA; Yusoff ZB; Hassali MA; Othman SB; Weiderpass E
Asian Pac J Cancer Prev; 2012; 13(9):4373-8. PubMed ID: 23167346
[TBL] [Abstract][Full Text] [Related]
15. Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate.
Colović R; Micev M; Matić S; Colović N; Grubor N; Atkinson HD
Vojnosanit Pregl; 2013 Feb; 70(2):225-8. PubMed ID: 23607193
[TBL] [Abstract][Full Text] [Related]
16. 1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma.
Rodríguez-Gutiérrez R; Zapata-Rivera MA; Quintanilla-Flores DL; Camara-Lemarroy CR; Lavalle-Gonzalez FJ; González-González JG; Villarreal-Pérez JZ
BMC Endocr Disord; 2014 Apr; 14():32. PubMed ID: 24721620
[TBL] [Abstract][Full Text] [Related]
17. A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone-related peptides.
Kampfenkel T; Baraniskin A; Teschendorf C; Schmiegel W; Massenkeil G
Acta Haematol; 2010; 124(1):57-60. PubMed ID: 20616540
[TBL] [Abstract][Full Text] [Related]
18. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
[TBL] [Abstract][Full Text] [Related]
19. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
